Loss of CD45 cell surface expression in canine T-zone lymphoma results from reduced gene expression by Martini, V et al.
Contents lists available at ScienceDirect
Veterinary Immunology and Immunopathology
journal homepage: www.elsevier.com/locate/vetimm
Research paper
Loss of CD45 cell surface expression in canine T-zone lymphoma results
from reduced gene expression
V. Martinia,⁎, M. Cozzia, A. Aricòb, G. Dalla Rovereb, A. Poggic, F. Albonicoa, M. Mortarinoa,
E. Ciusanid, L. Aresub, S. Comazzia
a Department of Veterinary Medicine, University of Milan, via Celoria 10, 20133 Milan, Italy
b Department of Comparative Biomedicine and Food Science, University of Padua, via dell’Università 16, 35020 Legnaro, Padua, Italy
c Department of Veterinary Sciences, University of Turin, Largo P. Braccini 2, 10095 Grugliasco, Turin, Italy
d Laboratory of Clinical Pathology and Medical Genetics, Neurological Institute Foundation “Carlo Besta”, via Celoria 11, 20133 Milan, Italy
A R T I C L E I N F O
Keywords:
CD45
Protein expression
mRNA
DNA transcription
Lymphoma
A B S T R A C T
Canine T-zone lymphoma (TZL) is a peculiar lymphoma subtype characterized by an indolent clinical course and
aberrant CD45-negative phenotype, commonly recognized by flow cytometry (FC). Recent studies have
described clinical presentation and behavior, but to date the mechanisms behind the loss of CD45 protein
expression have never been investigated.
The aims of this study were: 1) to confirm the absence of CD45 in canine TZL via the concomitant use of FC
and immunohistochemistry with two different sources of antibody; and 2) to investigate the amount of CD45
transcript and the presence of CD45 gene in the neoplastic cells of dogs affected by TZL.
57 lymph node aspirates were included in the present study: 40 (70.2%) TZLs, 7 (12.3%) high grade T-cell
lymphomas and 10 (17.5%) reactive lymph nodes. Neoplastic cells and normal T-cells were isolated from TZL
and reactive lymph nodes, respectively, via cell sorting. Immunohistochemistry was performed on 2 TZL, 2
reactive lymph nodes and 2 Peripheral T-cell Lymphomas. Total RNA and genomic DNA were extracted from
lymph-nodes aspirates. Two different quantitative real-time PCR experiments were designed, to determine the
amount of the CD45 transcript and of the corresponding gene fragment.
All TZL cases were negative for CD45 at immunohistochemistry. CD45 transcript amount was significantly
lower in TZL compared to controls (p < 0.001). This difference was not significant (p = 0.584) for CD45 DNA
load, that was similar between TZL and controls. Moreover, CD45 transcript amount was inversely correlated
with the percentage of neoplastic cells in each TZL sample (p = 0.010).
These results confirm that CD45 protein is lacking on cell surface irrespective of the technique and antibody
source adopted. This phenotypic aberrancy is apparently due to the absence of gene transcription, as CD45 DNA
was present, whereas CD45 transcript was virtually absent in the neoplastic cells. The data here reported support
further studies investigating possible factors impairing CD45 gene transcription.
1. Introduction
Dogs are frequently affected by hematopoietic malignancies, with
lymphoma being the most represented. Nevertheless, many different
entities are grouped together under the diagnosis of lymphoma,
showing different clinical presentation and outcome (Valli et al., 2013).
Small clear cell/T-zone lymphoma (TZL) subtype has been recently
identified as a unique entity with a peculiar disease distribution at onset
and with a typical indolent clinical course (Seelig et al., 2014; Martini
et al., 2015a). Histologically, TZL shows neoplastic cells expanding the
paracortex and medullary cords without effacing the nodal architec-
ture; neoplastic cells are small lymphocytes with sharp, shallow nuclear
indentations, unapparent nucleoli and a moderate volume of pale
cytoplasm. Mitoses are rare (Valli et al., 2006). Cytological aspirates
in dogs diagnosed with TZL are characterized by a prevalent population
of small lymphoid cells with a clear cytoplasm and frequent hand
mirror shape (“small clear cells” appearance). The mitotic index is low
(Fournel-Fleury et al., 2002). Finally, a peculiar phenotype has been
identified by flow cytometry (FC), characterized by the expression of a
variable number of T-cell markers and loss of expression of CD45
(Martini et al., 2015b; Seelig et al., 2014).
CD45 is a transmembrane protein tyrosine phosphatase expressed
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by the leukocytes surface in many different species, including dog
(Goto-Koshino et al., 2014). In humans, alternative RNA splicing causes
the generation of various CD45 isoforms, differing for molecular weight
and biological activity (Dupéré-Minier et al., 2010). Accordingly, two
major CD45 isoforms (CD45RA and CD45R0) have been described in
dog and expression patterns are different depending on leukocytes
subclasses and activation status (Goto-Koshino et al., 2014).
Historically, most of the studies have been centred to explain the
role of CD45 either in cell maturation or in signal transduction of T- and
B-cells after antigenic stimulation (Pingel and Thomas, 1989; Kishihara
et al., 1993; Byth et al., 1996), whereas more recently CD45 has been
proposed as apoptosis regulator (Lesage et al., 1997; Fortin et al., 2002;
Pang et al., 2009).
CD45-negative hematopoietic neoplasms other than canine TZL
have been reported both in humans (Ozdemirli et al., 1996; Ratei
et al., 1998; Kumar et al., 2005; Wang et al., 2015) and dogs (Gelain
et al., 2008; Williams et al., 2008), but the mechanisms underlying this
phenotypic aberrancy have not been investigated. To test this, the
present study has been organized in different tasks. The first aim is to
confirm the absence of CD45 at the protein level in a group of dogs with
TZL via the concomitant use of FC and immunohistochemistry with two
different sources of antibody. Based on of the absence of CD45 protein
in cTZL, subsequently the amount of CD45 transcript and the presence
of CD45 gene will be investigated in the same cohort of dogs. For the
purpose of the study a control group composed by normal sorted T-
cells, high grade T-cell lymphomas and normal lymph nodes has been
selected. This stepwise approach will outline the possible origin of
CD45 protein loss, whether associated to genetic or transcriptional or
post-translational modifications.
2. Materials and methods
2.1. Case selection
Samples from the present study were collected from the flow
cytometric diagnostic services of Department of Veterinary Medicine
(University of Milan, Milan, Italy) and Department of Veterinary
Sciences (University of Turin, Grugliasco, Turin, Italy). Consecutive
cases with a final diagnosis of TZL based on cytological appearance and
FC immunophenotype (Martini et al., 2015b) were included. In addi-
tion, cases of non-neoplastic lymph node and of high grade T-cell
lymphoma showing CD45 expression were included as controls. When
available, histopathological sections of the same cases were considered
to confirm the diagnosis and perform immunohistochemical analyses.
All dogs were privately owned and sampled for diagnostic purposes
with a written informed consent of the owners. Thus, a formal approval
of the Institution Committee for Animal Care was not required.
2.2. Flow cytometry
Lymph node aspirates collected into 1 ml RPMI tubes (Sigma
Aldrich, St. Louis, MO, USA) were processed for FC as already described
(Gelain et al., 2008), using a wide antibody panel (Table 1). All
antibodies had been previously titred to choose the optimal working
dilutions. A multicolour approach was used, allowing the assessment of
the contemporary expression of different antigens in the same cellular
population (Martini et al., 2015b). If necessary, RBCs were lysed by
means of a buffer containing 8% ammonium chloride after antibody
incubation.
Samples were acquired either with a FACScalibur or a BD Accuri C6
(Becton Dickinson, San Josè, CA, USA) and analysed using the specific
software CellQuest or CFlow Plus (Becton Dickinson).
The percentage of CD45-negative neoplastic cells was obtained in all
the TZLs.
2.3. Cell sorting
Neoplastic cells (CD45-negative and CD5-positive) from a subset of
TZLs and normal T-cells (CD45-positive and CD5-positive) from non-
neoplastic lymph nodes were sorted using a fluorescence-activated cell
sorter (BD FACSVantage, BD Biosciences, San Josè, CA, USA). A
minimum sorting yield of 1 × 105 with more than 95% purity was
considered suitable for quantitative real-time PCR analysis.
2.4. Histopathology and immunohistochemistry
For histological examination, three μm sections were stained with
haematoxylin and eosin (HE).
For lymphoma phenotyping, a panel of antibodies was applied
including: monoclonal mouse anti-human CD3 (Clone F7.2.38, Dako,
Atlanta, Georgia, USA, T cells; diluted 1:100), monoclonal mouse
antihuman CD5 (Clone CD5/54/F6, Dako, T cells; diluted 1:100),
monoclonal mouse anti-human CD79acy (Clone HM57, Dako, all stages
of B cells; diluted 1:100) and CD20 epitope-specific rabbit antibody
(RB-9013-P, Thermo Fisher Scientific Inc., Cheshire, UK; mature B cells;
diluted 1:800). The primary antibody incubation step was performed by
an automated system for all antibodies (Ventana Medical Systems,
Tucson, Arizona, USA).
Immunohistochemical analysis for CD45 was performed using H2O2
3% in methanol for 30 min at room temperature for blocking endogen-
ous peroxidase activity. Sections underwent high temperature antigen
unmasking by incubation with citric acid buffer (pH 6) at 98 °C. The
antibody used was an anti-canine CD45, clone CA12.10C12 (Leukocyte
Antigen Biology Laboratory, UCDavis, Davis, CA, USA) (dilution 1:100).
Antibody was detected using an avidine-biotine-peroxidase complex
technique with the Vectastain Elite ABC Kit (Vector Laboratories Inc.,
Burlingame, California, USA). For negative controls, the primary anti-
body was excluded during the process. Membranous immunolabelling
of the antibodies was evaluated in neoplastic cells in lymphomas and in
the control lymph nodes. Evaluation consisted of qualitative assessment
of cell types and location.
2.5. Quantitative real-time RT-PCR for CD45 transcript
The transcript analysis was performed on lymph node aspirates
diluted in RNAlater® (Applied Biosystems, Life Technologies, Carlsbad,
CA) and stored at −20 °C until processing. The total RNA was isolated
from cell pellets using the RNeasy Mini Kit (Qiagen, Milan, Italy)
according to the manufacturer’s instructions. To avoid genomic DNA
contamination, on-column DNase digestion with the RNase-Free DNase
(Qiagen) set was performed. Total RNA concentration and quality were
measured with a Nanodrop ND-1000 spectrophotometer (Nanodrop
Technologies, Wilmington, DE). First-strand cDNA was synthesised
from 100 ng of total RNA using High Capacity cDNA Reverse
Transcription Kit (Invitrogen, Life Technologies, Carlsbad, CA) accord-
Table 1
antibody panel used to label lymph node aspirates collected into RPMI tubes from dogs
with suspected lymphoma.
Target
molecule
Antibody clone Source Specificity
CD45 YKIX716.13 Serotec, Oxford,
UK
All leukocytes
CD3 CA17.2A12 Serotec T-cells
CD5 YKIX322.3 Serotec T-cells and a subset of B-
cells
CD4 YKIX302.9 Serotec T-helper cells and
neutrophils
CD8 YCATE55.9 Serotec T-cytotoxic cells
CD21 CA2.1D6 Serotec Mature B-cells
CD34 1H6 BD Pharmingen Precursors
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ing to the manufacturer’s protocol. The generated cDNA was used as
template for quantitative real-time RT-PCR (qRT-PCR) in a LightCycler
480 Instrument (Roche Diagnostics, Basel, Switzerland) using standard
PCR conditions. The qRT-PCR reactions consisted of 5 μl of Platinum
SYBR Green qPCR SuperMix-UDG (Invitrogen, Life Technologies,
Carlsbad, CA), 0.3 μl of forward and reverse primers (10 μM) (the
primer combination and final concentrations were optimized during
assay setup) and 2.5 μl of diluted (1–40) cDNA. The primers were
designed using Primer Express 2.0 (Applied Biosystem, Life
Technologies, Carlsbad, CA). Canine CD45 was amplified using the
primer pair 5′- ATG GAG ATG CAG GGT CAA AT-3′ (forward) and 5′-
GCA ATG TAT TTC CTG GGT TCT T-3′ (reverse). Primer pairs were
designed on exon 19 and 20, shared by the two CD45 variants. In
addition, these exons spare an intronic region of> 3800 bp thus
excluding the amplification of contaminant genomic DNA. Calibration
curves using a 7-fold serial dilution (1:2) of a cDNA pool revealed PCR
efficiencies of 99.5%. Canine transmembrane BAX inhibitor motif
containing 4 (CGI-119) was chosen as reference gene for the absence
of pathological state dependent differences in mRNA expression, as
reported by Aricò et al. (2013). ΔΔCt method (Livak and Schmittgen,
2001) was used for the relative quantification of mRNA, ultimately
expressed as Relative Expression (RE).
2.6. Quantitative real-time PCR for CD45 DNA
An aliquot of lymph node aspirates was stored at −20 °C until
processing for DNA load analysis. Genomic DNA was extracted from cell
pellets using DNeasy® Blood & Tissue kit (Qiagen) following the man-
ufacturer’s instructions. Total DNA concentration and quality were
measured with a Nanodrop ND-1000 spectrophotometer (Nanodrop
Technologies). Primers were designed using Primer3web (primer3.u-
t.ee) based on the corresponding canine genome project gene sequences
available through Ensembl web site (www.ensembl.org). Specific
primers for CD45 were designed as follows: primer pair CD45 5′-
AGCAAAGACACACGAAAGCC-3′ (forward) and 5′-GCAATGTATTT
CCTGGGTTCT −3′ (reverse) for the amplification of a fragment of
257 base pairs. In order to detect reference genes for normalization of
samples, primers targeting canine CGI-119 and canine GAPDH was
designed as described: primer pair CGI-119 5′-GGATTTTGTG
CTTGTCAGGAA-3′ (forward) and 5′-CACTGGGAGCTTAGCAATTACA-
3′ (reverse) for the amplification of a fragment of 279 base pairs; primer
pairs GAPDH 5′-GGAGAAAGCTGCCAAATATG-3′ (forward) and 5′-
ACCAGGAAATGAGCTTGACA-3′ (reverse) for the amplification of a
fragment of 194 base pairs (Mortarino et al., 2009). Quantitative Real-
Time PCR was performed in 14 μl with 1 μl of target DNA, using 1x Eva
Green mix (Biorad, Segrate, Milan, Italy), and 10 μM of each primer.
Samples were tested in duplicate. In order to evaluate the PCR
efficiency using a relative standard curve, dilution series were prepared
by performing four fold serial dilution (1:10) of a control sample.
Efficiency was 100.47% for CD45, 102.16% for CGI119 and 98.70 for
GAPDH. ΔΔCt method (Livak and Schmittgen, 2001) was used to
describe the CD45 DNA load to the reference genes, expressed as
Relative Quantification (RQ).
2.7. Amplicon sequencing
The specificity of the amplification for CD45 transcript and DNA
was checked by amplicon DNA sequencing. Briefly, the reaction
mixtures after PCR were run by 2.5% agarose gel electrophoresis, and
the UV-visualized bands were purified using the QiaquickTM Gel
Extraction Kit (Qiagen GmbH, Hilden, Germany). The concentration
of the purified amplicons was assessed using a ND-100 spectrophot-
ometer (NanoDrop, Wilmington, DE USA). Then, each amplicon was
sequenced by Sanger chemistry (Eurofins Genomics S.r.l., Vimodrone,
MI, Italy). The obtained sequences were aligned with the expected
target sequence using BLAST (https://blast.ncbi.nlm.nih.gov).
2.8. Statistical analysis
Data distribution was assessed via Shapiro-Wilk test for each subset.
Kruskal-Wallis test was used to compare CD45 transcript amount
among TZL, cells CD5-positive sorted from reactive lymph nodes and
CD45-positive high grade T-cell lymphomas. A Mann-Whitney test was
used to compare CD45 transcript amount between TZL samples with<
95% and>95% neoplastic cells.
The Kruskal-Wallis test was also performed to compare CD45 DNA
load among TZL, reactive lymph nodes and cells CD45-negative and
CD5-positive sorted from TZL.
A non-parametric Spearman correlation analysis was used to
determine the potential relationship between CD45 transcript amount
and percentage of neoplastic cells in the TZL samples.
All analyses were performed with standard statistical software (SPSS
v20.0 for Windows) and significance was set at p≤ 0.05 for all tests.
3. Results
Fine needle aspirates from an enlarged lymph node were obtained
from 57 dogs and included in the study. Diagnoses were as follow: 40
(70.2%) TZLs, 7 (12.3%) high-grade T-cell lymphomas and 10 (17.5%)
hyperplastic lymphadenopathy. Normal and neoplastic cells were
obtained with cell sorting from 3 non-neoplastic lymph nodes and 3
TZLs, respectively. In addition, paraffin embedded lymph nodes from 2
cases diagnosed as reactive hyperplasia, 2 as Peripheral T-cell lympho-
mas (PTCL) and 2 as TZL were available for immunohistochemical
analysis.
According to FC analysis, the percentage of CD45-negative neoplas-
tic cells in the TZLs was 80.54 ± 14.9% (median 82.6%; min-max
30.77–98.04%). The composition of the residual CD45-positive popula-
tion was heterogeneous. One sample had a predominant (94.5%)
population of granulocytes and the lymphoid population was composed
of T-cytotoxic (4.8%), T-helper (1.4%) and B-cells (0.34%): this sample
was highly hemo-contaminated at cytological examination. For the
remaining samples, the residual CD45-positive population was com-
posed of lymphoid cells alone, with a mean percentage of
36.57 ± 17.31% (median 33.22%; min-max 1.40–67.41%) of B-cells,
34.72 ± 19.45% (median 33.63%; min-max 1.89–92.09%) of T-helper
cells, and 18.75 ± 14.64% (median 12.91%; min-max 0.72–60.15%)
of T-cytotoxic cells. As expected, the CD45-negative and CD5-positive
cells were not detected either in the reactive lymph nodes or in the
high-grade T-cell lymphomas.
Immunohistochemical results showed a diffuse CD45 membranous
expression in PTCLs. In the reactive lymph nodes, CD45 positive cells
were located both in the paracortex and in the germinal centres (Fig. 1);
cells in the marginal and mantle zones were also CD45 positive, even
with a lower intensity. TZLs were diffusely negative (Fig. 2).
Amplicon DNA sequencing confirmed (99–100%) the specificity of
the amplification for both CD45 targets.
Data concerning CD45 transcript amount were obtained from 41
cases, including 31 (75.6%) TZLs, 7 (17.1%) high grade T-cell
lymphomas, and 3 (7.3%) sorted normal T cells. The mean neoplastic
cells percentage in TZLs undergoing transcript analysis was
80.23 ± 15.61% (median 82.6%; min-max 30.77–98.04%); in parti-
cular, 26 (83.9%) cases had< 95% neoplastic cells, whereas the
remaining 5 (16.1%) cases had>95% neoplastic cells. Results of
transcript analysis are shown in Fig. 3.
A significant difference in the CD45 transcript amount was detected
among TZLs, normal T cells and high grade T-cell lymphomas
(p < 0.001). mRNA levels were significantly lower in TZLs than in
normal T cells and high grade T-cell lymphomas (p < 0.001), respec-
tively. No significant difference was found between normal T cells and
high grade T-cell lymphomas (P = 0.138).
When exploring the correlation between the amount of CD45
transcript and the percentage of the neoplastic cells in TZL, a significant
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inverse correlation was detected between CD45 mRNA data and the
percentage of neoplastic cells (p = 0.010). In addition, the amount of
CD45 transcript was higher in the 26 TZL samples with<95%
neoplastic cells (mean = 0.37 ± 0.29) than in the 5 TZL samples
with> 95% neoplastic cells (mean = 0.23 ± 0.16), although the
difference was not statistically significant.
Data concerning CD45 DNA load were obtained for 33 samples,
including 24 (72.7%) TZLs, 3 (9.1%) CD45-negative cells and CD5-
positive cells sorted from TZLs and 6 (18.2%) non-neoplastic lymph
nodes. The mean neoplastic cells percentage in TZLs undergoing
DNA analysis was 81.95 ± 9.88% (median 83.26%; min-max
30.77–96.5%). Results are shown in Fig. 3. The differences among
subsets were not significant irrespective of the reference gene consid-
ered (p = 0.165 for CGI-119 and p = 0.895 for GAPDH).
4. Discussion
The absence of CD45 expression in canine TZL has been previously
described to demonstrate the diagnostic efficiency and the staging
prediction (Martini et al., 2015a,b; Seelig et al., 2014). Interestingly, all
these studies assessed the expression of the protein by FC using the
same antibody clone (YKIX716.13), although conjugated with different
fluorochromes. As a consequence, protein modifications preventing
antibody binding during FC processing could not be completely
excluded based on the published literature. In the present study, we
analysed two cases of TZL via immunohistochemistry using a different
antibody clone and results confirmed FC analysis. Both techniques and
clones could not detect CD45 protein, thus confirming the lack of CD45
protein expression in canine TZL. Although no specific information was
available about the sequence recognized by the two different anti-
bodies, these preliminary results suggested that partial modification of
the protein is unlikely and supported the hypothesis of a complete loss
of CD45 in TZLs.
To investigate this scenario, we inquired whether CD45 transcript
was also reduced in canine TZL and consequently if CD45 gene was still
represented in the genome of the neoplastic cells. To answer this
hypothesis, we designed two quantitative real-time PCR experiments in
order to investigate the transcript amount and DNA load, respectively.
In the study setting a major limiting factor was related to the
selection of control lymphocytes for both transcript and DNA analyses.
Indeed, CD45 is differently expressed in the various canine leukocyte
subclasses, also depending on the activation status (Goto-Koshino et al.,
2014), and CD45 transcript amount may vary accordingly. In particu-
lar, CD45 is expressed at lower levels in B-cells than in T-cells (Comazzi
et al., 2006): thus, inclusion of B-cells in the control group for transcript
amount analysis would have affected results concealing possible
differences between TZLs and controls. Respect to this, we selected as
control high grade T-cell lymphomas and a pure T-cell population
obtained by cell sorting from non-neoplastic lymph nodes.
Based on our results, CD45 transcript amount resulted significantly
lower in TZLs compared to high-grade T-cell lymphomas and normal T-
cells. Albeit a small CD45 transcript amount was detected in TZLs, this
might be associated to the contamination of relevant residual normal
lymphocytes in the samples obtained. This was well demonstrated when
Fig. 1. Representative image of CD45 protein staining in a reactive lymphoid
hyperplasia.T-lymphocytes within the paracortex and B-lymphocytes in the follicles show
a diffuse CD45 immunolabelling. Bar: 500 μm.
Fig. 2. Representative image of CD45 protein staining in a T-zone lymphoma.Neoplastic
lymphocytes are negative to CD45 immunolabelling. Bar: 500 μm.
Fig. 3. CD45 transcript and DNA amount in canine T-zone lymphomas and in controls.Panel A: CD45 transcript amount in canine T-zone lymphomas, sorted CD5-positive cells from
reactive lymph nodes and high-grade T-cell lymphomas; CGI-119 was used as a housekeeping gene; CD45 transcript amount was significantly lower in T-zone lymphomas than in the
other two groups, respectively (p < 0.001). Panel B: CD45 DNA load in canine T-zone lymphomas, sorted neoplastic cells from T-zone lymphomas and reactive lymph nodes; CGI-119
was used as a reference gene; no significant difference in CD45 DNA load was found among groups. Panel C: CD45 DNA load in canine T-zone lymphomas, sorted neoplastic cells from T-
zone lymphomas and reactive lymph nodes; GAPDH was used as a reference gene; no significant difference in CD45 DNA load was found among groups.
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comparing the CD45 gene expression to the number of neoplastic cells
in these tumors. The lowest CD45 transcript amounts were associated to
TZLs with the highest percentage of neoplastic cells and consequently
the lowest percentage of residual lymphocytes. Taken together, these
results suggest that CD45 transcript is virtually absent in TZL neoplastic
cells.
For DNA load analysis, high grade T-cell lymphomas were excluded
as controls due to the possible presence of genetic abnormalities that
occur in cancer cells, leading to unpredictable biases. In contrast, the
selection of non-neoplastic lymph nodes as controls, potentially should
not interfere with this result, as variations in genes copy number are not
expected in reactive lymph nodes, at least in the CD45 gene. However,
the silico identification of the reference gene for DNA load analysis was
complicated by two biological variables. First, copy number variations
may eventually occur at gene level biasing the results and second, no
relevant data are published about genetic modifications of canine TZL.
Thus, primers for two different genes were designed for our analysis
and results showed a similar load in TZLs and controls, irrespective of
the reference gene used, demonstrating that CD45 gene is not deleted in
canine TZL.
Primers design was also challenging, as different isoforms of CD45
exist obtained by alternative RNA splicing (Dupéré-Minier et al., 2010)
and the gene comprises many introns (www.ensembl.org). Further-
more, we designed primers that were adapted to amplify a transcript
fragment common to all CD45 isoforms, and a gene segment specifically
encoding for the transcript fragment was amplified. By doing this, we
reached a double goal: first, we included all CD45 isoforms in our
analysis; second, we described the different fate of a single sequence at
two different levels (transcript and DNA).
Many different mechanisms may cause CD45 gene transcription
switch off, including genetic, epigenetic, and genomic abnormalities.
Still, gross chromosome or gene deletions are unlikely. Indeed, we were
able to detect the presence of CD45 gene in TZL cells. In addition, Seelig
et al. (2014) report that there is no evident loss of the telomeric end of
chromosome 7, where CD45 is located, although no scientific data are
described in their publication. All other mechanisms are still possible
and should be evaluated via further studies.
Different studies in human medicine investigated the importance of
CD45 in normal T- and B-cells, highlighting its role in cell maturation,
signal transduction and apoptosis mediator (Pingel and Thomas, 1989;
Kishihara et al., 1993; Byth et al., 1996; Lesage et al., 1997; Fortin
et al., 2002; Pang et al., 2009). Its involvement in neoplastic transfor-
mation may be suspected, but this has never been demonstrated.
Interestingly, different oncogenes are located near CD45 gene in canine
chromosome 7, including ABL2, AKT3, YES1 and some members of the
Ras family (www.ensembl.org). These oncogenes play a role in cancer
development in human leukemias and lymphomas (Mao et al., 2003;
Huang et al., 2010; Kim et al., 2015; Roberts and Mullighan, 2015).
Perturbation of methylation on the promoter regions of these genes or
genomic abnormalities on a large segment of canine chromosome 7
may cause impaired transcription of any of these oncogenes participat-
ing to the tumorigenesis. Thus, it cannot be excluded that the absence of
CD45 protein is only a phenotypic epiphenomenon, with minimal
involvement in the tumor biology. Further studies are needed, assessing
possible alterations in oncogenes activation.
The whole CD45 gene sequencing would probably solve the
limitations of our study where only a fragment of CD45 gene
specifically encoding for the transcript fragment selected was amplified.
Thus, mutations, short deletions or base pair variations may occur
upstream of the amplified fragment, remaining unnoticed to our
analysis, but still preventing gene transcription.
In conclusion, the present study confirms the lack of CD45 protein
in canine TZL, irrespective of the different techniques and antibody
clones used. Based on our results, this phenotypic aberrancy is likely
due to the absence of gene transcription, as CD45 DNA was present,
whereas CD45 transcript was virtually absent in the neoplastic cells.
Further studies are needed to identify the abnormalities causing the
lack of transcription.
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